MA34285B1 - Traitement de maladies autoimmunes - Google Patents
Traitement de maladies autoimmunesInfo
- Publication number
- MA34285B1 MA34285B1 MA35416A MA35416A MA34285B1 MA 34285 B1 MA34285 B1 MA 34285B1 MA 35416 A MA35416 A MA 35416A MA 35416 A MA35416 A MA 35416A MA 34285 B1 MA34285 B1 MA 34285B1
- Authority
- MA
- Morocco
- Prior art keywords
- alkyl
- group
- halogen
- phenyl
- alcoxy
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- -1 C1-4 alcohoxyl Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical group [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical class N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 101710189490 Spore cortex-lytic enzyme Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical class O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 abstract 1
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical class O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/30—Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10162079 | 2010-05-06 | ||
| PCT/EP2011/057203 WO2011138393A1 (en) | 2010-05-06 | 2011-05-05 | Treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34285B1 true MA34285B1 (fr) | 2013-06-01 |
Family
ID=42199281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35416A MA34285B1 (fr) | 2010-05-06 | 2011-05-05 | Traitement de maladies autoimmunes |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130172297A1 (https=) |
| EP (1) | EP2566470A1 (https=) |
| JP (1) | JP2013530937A (https=) |
| KR (1) | KR20130066630A (https=) |
| CN (1) | CN102869353A (https=) |
| AU (1) | AU2011249784B2 (https=) |
| BR (1) | BR112012028190A2 (https=) |
| CA (1) | CA2795394A1 (https=) |
| CL (1) | CL2012003091A1 (https=) |
| CR (1) | CR20120566A (https=) |
| CU (1) | CU20120154A7 (https=) |
| EA (1) | EA201201514A1 (https=) |
| EC (1) | ECSP12012312A (https=) |
| IL (1) | IL222690A0 (https=) |
| MA (1) | MA34285B1 (https=) |
| MX (1) | MX2012012926A (https=) |
| NZ (1) | NZ603999A (https=) |
| PE (1) | PE20130612A1 (https=) |
| PH (1) | PH12012502418A1 (https=) |
| SG (1) | SG185746A1 (https=) |
| TN (1) | TN2012000509A1 (https=) |
| TW (1) | TW201201814A (https=) |
| WO (1) | WO2011138393A1 (https=) |
| ZA (1) | ZA201207710B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI519539B (zh) * | 2010-12-21 | 2016-02-01 | Kyorin Seiyaku Kk | Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof |
| US9289494B2 (en) * | 2013-11-20 | 2016-03-22 | RestorTears, LLC | Method of treating ocular disorders with compounds found in Harderian gland secretions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2461212C (en) | 2001-09-27 | 2010-08-17 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same |
| DE60235900D1 (de) * | 2001-09-27 | 2010-05-20 | Kyorin Seiyaku Kk | Osuppressivum |
| JP4571497B2 (ja) * | 2002-09-19 | 2010-10-27 | 杏林製薬株式会社 | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| BRPI0407658A (pt) * | 2003-02-18 | 2006-02-21 | Kyorin Seiyaku Kk | derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico |
| EP1628957B1 (en) * | 2003-05-26 | 2010-09-29 | Takeda Pharmaceutical Company Limited | Sulfopyrroles |
| ATE449069T1 (de) | 2003-08-28 | 2009-12-15 | Novartis Pharma Gmbh | Aminopropanolderivate |
| CA2553704C (en) * | 2004-02-11 | 2011-04-19 | Basilea Pharmaceutica Ag | Substituted benzimidazoles and their use for inducing apoptosis |
| WO2006041015A1 (ja) * | 2004-10-12 | 2006-04-20 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| ES2529724T3 (es) * | 2005-09-09 | 2015-02-25 | Novartis Ag | Tratamiento de enfermedades autoinmunes |
-
2011
- 2011-05-05 KR KR1020127031868A patent/KR20130066630A/ko not_active Withdrawn
- 2011-05-05 MA MA35416A patent/MA34285B1/fr unknown
- 2011-05-05 MX MX2012012926A patent/MX2012012926A/es not_active Application Discontinuation
- 2011-05-05 JP JP2013508502A patent/JP2013530937A/ja active Pending
- 2011-05-05 EP EP11723889A patent/EP2566470A1/en not_active Withdrawn
- 2011-05-05 BR BR112012028190A patent/BR112012028190A2/pt not_active IP Right Cessation
- 2011-05-05 EA EA201201514A patent/EA201201514A1/ru unknown
- 2011-05-05 PH PH1/2012/502418A patent/PH12012502418A1/en unknown
- 2011-05-05 TW TW100115816A patent/TW201201814A/zh unknown
- 2011-05-05 US US13/643,320 patent/US20130172297A1/en not_active Abandoned
- 2011-05-05 AU AU2011249784A patent/AU2011249784B2/en not_active Ceased
- 2011-05-05 NZ NZ603999A patent/NZ603999A/en not_active IP Right Cessation
- 2011-05-05 PE PE2012002122A patent/PE20130612A1/es not_active Application Discontinuation
- 2011-05-05 CA CA2795394A patent/CA2795394A1/en not_active Abandoned
- 2011-05-05 CN CN2011800224469A patent/CN102869353A/zh active Pending
- 2011-05-05 WO PCT/EP2011/057203 patent/WO2011138393A1/en not_active Ceased
- 2011-05-05 SG SG2012086526A patent/SG185746A1/en unknown
-
2012
- 2012-10-15 ZA ZA2012/07710A patent/ZA201207710B/en unknown
- 2012-10-23 TN TNP2012000509A patent/TN2012000509A1/en unknown
- 2012-10-25 IL IL222690A patent/IL222690A0/en unknown
- 2012-11-05 CU CU2012000154A patent/CU20120154A7/es unknown
- 2012-11-06 CR CR20120566A patent/CR20120566A/es unknown
- 2012-11-06 CL CL2012003091A patent/CL2012003091A1/es unknown
- 2012-11-27 EC ECSP12012312 patent/ECSP12012312A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011138393A1 (en) | 2011-11-10 |
| EP2566470A1 (en) | 2013-03-13 |
| ECSP12012312A (es) | 2012-12-28 |
| CA2795394A1 (en) | 2011-11-10 |
| CU20120154A7 (es) | 2013-03-27 |
| TW201201814A (en) | 2012-01-16 |
| NZ603999A (en) | 2014-06-27 |
| CR20120566A (es) | 2013-01-09 |
| JP2013530937A (ja) | 2013-08-01 |
| IL222690A0 (en) | 2012-12-31 |
| ZA201207710B (en) | 2013-06-26 |
| PE20130612A1 (es) | 2013-06-06 |
| EA201201514A1 (ru) | 2013-05-30 |
| MX2012012926A (es) | 2012-12-17 |
| KR20130066630A (ko) | 2013-06-20 |
| AU2011249784A1 (en) | 2012-12-20 |
| PH12012502418A1 (en) | 2018-03-21 |
| SG185746A1 (en) | 2013-01-30 |
| US20130172297A1 (en) | 2013-07-04 |
| AU2011249784B2 (en) | 2014-03-06 |
| CL2012003091A1 (es) | 2013-03-22 |
| TN2012000509A1 (en) | 2014-04-01 |
| CN102869353A (zh) | 2013-01-09 |
| BR112012028190A2 (pt) | 2016-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117694A1 (es) | COMPUESTO AGONISTA DEL RECEPTOR THRb Y PREPARACIÓN Y USO DEL MISMO | |
| CA2793311C (en) | Modulators of hec1 activity and methods therefor | |
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| MA29684B1 (fr) | Composes de spiro-oxindole et utilisations associees en tant qu'agents therapeutiques | |
| RU2009105403A (ru) | Твердая фармацевтическая композиция для перорального введения (варианты) | |
| JP2006524660A5 (https=) | ||
| FI4094804T3 (fi) | Aryyliamidijohdannainen, jolla on kasvaimia estävä vaikutus | |
| RU2013154412A (ru) | Аминопиримидины в качестве ингибиторов syc | |
| TWI598098B (zh) | 脂質異常症治療劑 | |
| PE20151091A1 (es) | Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes | |
| NO20073853L (no) | Faste, oralt applikerbare farmasoytiske administreringsformer inneholdende nvaroksaban med modifisert frigivelse | |
| JP2013519675A5 (https=) | ||
| JP2019510027A5 (https=) | ||
| NO20081724L (no) | Stabil farmasoytisk sammensetning omfattende et pyrimidin-sulfamid | |
| RU2011106364A (ru) | Жидкие составы | |
| EP4192455A4 (en) | Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration | |
| JP2019501130A5 (https=) | ||
| RU2015121043A (ru) | Производные фенилэтилпиридина в качестве ингибиторов PDE-4 | |
| AR083020A1 (es) | Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden | |
| PE20050692A1 (es) | Compuestos organicos | |
| MA34285B1 (fr) | Traitement de maladies autoimmunes | |
| AR072611A1 (es) | Compuestos de 3-(fenoxifenilmetil)pirrolidina, un metodo para su preparacion, intermediario de sintesis y su proceso de obtencion, composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de 5-ht y ne. | |
| RU2015141360A (ru) | Ингибиторы тирозинкиназы брутона | |
| EP3906229A4 (en) | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENT | |
| JP2021503451A5 (https=) |